Telix Pharmaceuticals Limited (TLX) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
TLX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Telix Pharmaceuticals Limited (TLX) trades at a price-to-earnings ratio of 105.7x, with a stock price of $10.68 and trailing twelve-month earnings per share of $0.20.
The current P/E is 17% above its 5-year average of 90.1x. Over the past five years, TLX's P/E has ranged from a low of 83.1x to a high of 97.2x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, TLX trades at a 382% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, TLX commands a significant premium over the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TLX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TLX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $12B | 17.3 | 0.34Best | +58% | |
| $1B | 48.6 | - | +10% | |
| $6B | 27.3 | - | -22% | |
| $279B | 20.3 | 1.32 | +22% | |
| $115B | 16.3 | - | +178%Best | |
| $310B | 36.4 | 3.08 | +36% | |
| $29B | 13.9Lowest | - | +5% | |
| $109B | 34.0 | 2.29 | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TLX Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $16.07 | $0.19 | 83.1x | -8% |
| FY2024 Q4 | $15.40 | $0.16 | 97.2x | +8% |
Average P/E for displayed period: 90.1x
See TLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTLX — Frequently Asked Questions
Quick answers to the most common questions about buying TLX stock.
Is TLX stock overvalued or undervalued?
TLX trades at 105.7x P/E, near its 5-year average of 90.1x. The 100th percentile ranking places valuation within normal historical bounds.
How does TLX's valuation compare to peers?
Telix Pharmaceuticals Limited P/E of 105.7x compares to sector median of 21.9x. The premium reflects expected growth above peers.
What is TLX's PEG ratio?
TLX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.